CClinicalTrials.gg
WithdrawnNCT03465345Updated Aug 3, 2018

Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients

A Phase 1 interventional study of Metformin and Oligomeric Procyanidin Complex in Prostate Cancer, sponsored by Medical University of South Carolina. Withdrawn at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-03.

Sponsored by Medical University of South Carolina · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study was stopped to pursue a new treatment plan with a new study.
Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The overall goal of this study is to identify a safe dose of metformin, in combination with oligomeric procyanidin complex (OPC) for pharmacologic reduction of AGE levels in patients with prostate cancer.

Read the detailed description

AGEs (advanced glycation endpoints) are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The purpose of this study is to identify safe pharmaceutical agents that can reduce the AGE levels in subjects with advanced cancer.

02

Conditions studied

  • Prostate Cancer

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  1. Confirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancer.
  2. Subjects must be receiving ADT with a GnRH agonist or antagonist, with or without an anti-androgen, with a current testosterone level documented to be \<50ng/dL at enrollment. Subjects whose ADT is interrupted may enroll or continue on study as long as the testosterone is documented to remain \<50ng/dL for the entire duration of study participation. Subjects who have undergone orchiectomy are also eligible.
  3. Subjects must have adequate hematologic, renal, and hepatic function at baseline, as follows:

    • Hematology parameters: ANC >1000/mcL, platelets > 100,000/mcL, Hgb >8.0gm/dL
    • Renal Function: eGFR of ≥ 45mls/min using Cockkroft and Gault formula (see appendix C).
    • Liver Function: Total bilirubin ≤ULN, AST and ALT \<1.5xULN, Prior radiation therapy allowed
  4. Subjects may have diabetes mellitus but must not be taking metformin.
  5. Able to swallow and retain oral medication
  6. ECOG performance status of 0 - 2
  7. Ability to sign written informed consent
  8. Testosterone level \<50ng/dL at time of enrollment.
  9. Age 18 or older.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to grapes or grape seed
  2. Known hypersensitivity or intolerance to metformin.
  3. Any condition associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heart failure defined as NYHA Class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day).
  4. Prior cytotoxic chemotherapy for metastatic prostate cancer; prior treatment with genomically-targeted agents, or Provenge is allowed.
  5. History of receiving more than 2 classes of ADT.
  6. Current use of metformin, or strong antioxidants (extracts from grape seed, milk thistle; pine bark, green tea, saw palmetto; resveratrol; flavonoids; catechins; ellagic acid), large quantities of red grapes, white button mushrooms, red wine
  7. PSA doubling time of \<6 months, measured over the 3 months prior to enrollment.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Metformin + OPC dose escalation

    Drug: Metformin · Drug: Oligomeric Procyanidin Complex

Interventions

  • DrugMetformin

    Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.

  • DrugOligomeric Procyanidin Complex

    OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.

    Also known as: OPC

05

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of metformin in combination with OPC in PCa subjects.

    Time frame: 112 days

Secondary outcomes

  1. Correlation between changes to AGE level and changes to PSA.

    Time frame: 112 days

  2. Correlation between changes to AGE level and changes to BMI.

    Time frame: 112 days

  3. Correlation between changes to AGE level and changes to insulin resistance.

    Time frame: 112 days

  4. Correlation between changes to AGE level and changes to A1C.

    Time frame: 112 days

  5. Correlations between changes to AGE level and changes to testosterone.

    Time frame: 112 days

  6. Correlation between changes to AGE level and changes to diet.

    Time frame: 112 days

  7. Correlation between changes to AGE level and changes to quality of life.

    FACT-P and AUA questionnaires

    Time frame: 112 days

  8. Frequency of adverse events as assessed by CTCAE v. 4

    Toxicities will be tabulated by type and grade and the proportion of patients with grade 3, grade 4 or an SAE will be estimated with a 90% confidence interval.

    Time frame: 112 days

  9. Correlation between AGE levels and sRAGE (soluble receptor for AGE) expression and signaling.

    Time frame: 112 days

  10. Correlation between changes to AGE level and OPC metabolite levels.

    Time frame: 112 days

  11. Correlation between changes to AGE level and changes in the stool. microbiome.

    Time frame: 112 days

06

Study locations

1 site
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03465345
Lead sponsor
Medical University of South Carolina
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Jul 11, 2018
Primary completion
Jul 11, 2018
Completion
Jul 11, 2018
Last update
Aug 3, 2018

Study contacts

Michael Lilly, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion